Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an adjunctive treatment for Major Depressive Disorder (MDD)The PARADIGM program consists of three pivotal efficacy studies designed to assess CYB003’s impact on patients suffering from moderate to severe MDD who are inadequately responding to current antidepressant therapiesCybin also disclosed its unaudited financial results for the second quarter ending September 30, 2024, highlighting a cash position of C$154.3 million, with access to over C$217.7 million when factoring in …